Vildagliptin Compared to Pioglitazone in Combination With Metformin in Patients With Type 2 Diabetes

This study has been completed.
Information provided by:
Novartis Identifier:
First received: October 9, 2005
Last updated: August 21, 2008
Last verified: August 2008

Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a single oral drug. The purpose of this study is to assess the long-term safety and effectiveness of vildagliptin, an unapproved drug, compared to that of pioglitazone in lowering overall blood glucose levels when added to metformin in people with type 2 diabetes not at target blood glucose levels on metformin alone.

Condition Intervention Phase
Diabetes Mellitus, Type 2
Drug: vildagliptin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Vildagliptin Compared to Pioglitazone in Combination With Metformin in Patients With Type 2 Diabetes

Resource links provided by NLM:

Further study details as provided by Novartis:

Primary Outcome Measures:
  • Change from baseline in HbA1c at 52 weeks

Secondary Outcome Measures:
  • Adverse event profile after 52 weeks of treatment
  • Change from baseline in fasting plasma glucose at 52 weeks
  • Change from baseline in body weight at 52 weeks
  • Patients with endpoint HbA1c < 7% after 52 weeks
  • Patients with reduction in HbA1c >/= to 7% after 52 weeks

Estimated Enrollment: 588
Study Start Date: October 2005
Primary Completion Date: February 2007 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years to 77 Years
Genders Eligible for Study:   Both

Inclusion Criteria:

  • On a stable dose of metformin as defined by the protocol
  • Blood glucose criteria must be met
  • Body mass index (BMI) in the range 22-45

Exclusion Criteria:

  • History of type 1 diabetes
  • Pregnancy or lactation
  • Evidence of significant diabetic complications
  • Serious cardiovascular events within the past 6 months
  • Laboratory value abnormalities as defined by the protocol
  • Known sensitivity to pioglitazone
  • Other protocol-defined exclusion criteria may apply
  Contacts and Locations
Please refer to this study by its identifier: NCT00237237

United States, New Jersey
Novartis Pharmaceuticals
East Hanover, New Jersey, United States, 07936
Investigative Centers
Nurnberg, Germany
Sponsors and Collaborators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

No publications provided Identifier: NCT00237237     History of Changes
Other Study ID Numbers: CLAF237A2354
Study First Received: October 9, 2005
Last Updated: August 21, 2008
Health Authority: United States: Food and Drug Administration

Keywords provided by Novartis:
Type 2 diabetes

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions
Dipeptidyl-Peptidase IV Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on April 15, 2014